Important Program Updates
The following drugs are now incorporated under the Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategies (REMS) Program:
- SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII)
- SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII)
- SUBUTEX® (buprenorphine) Sublingual Tablet (CIII)
All REMS materials are now available at the new location.
The BTOD REMS Program's purpose is to inform healthcare professionals and patients about the safe use conditions and serious risks, including accidental overdose, misuse, and abuse, associated with buprenorphine‑containing transmucosal products indicated for the treatment of opioid dependence.
Clicking below will transfer you to BTODREMS.com
You are now leaving the SuboxoneREMS.com website. A link to the BTOD REMS Program Website is provided for your convenience. Indivior Inc. does not own, manage, or operate the BTOD REMS website and you are solely responsible for any and all interactions with BTODREMS.com; accordingly, please review the BTOD REMS website's privacy policy and terms of use.
CONTINUE TO BTOD REMS PROGRAM WEBSITE
NP-SBF-US-00039